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RECOGNIZING THE NEED FOR UNIFORM INTERNATIONAL
REGULATION OF DEVELOPING BIOTECHNOLOGY: A FOCUS ON
GENETIC EXPERIMENTATION

I. INTRODUCTION

As new developments in the field of recombinant DNA technology become commonplace in the international arena, the need
for a uniform system of regulatory laws that protect health and
human safety becomes readily apparent. Genetic technology and
its regulation pose a number of problematic issues. 1 These issues
include: risk to health and the environment, choices made by patients and consumers, property rights, confidentiality and ethics, to
name a few. 2 "Social, political and ethical controversy surrounds
most of the recent advances in scientists' abilities to understand
and manipulate genes on a molecular level."' 3 "Like most modern
technologies, [however,] biotechnology cannot be easily confined
within the borders of a single state." 4 When people, animals and
other organisms travel, they carry within them unique biotechnology products regulated by the laws of the region in which they are
developed. 5 Thus, regardless of the strengths or weaknesses of the
regulatory standards in any one region, those standards are routinely imposed upon the inhabitants of every region of the world
6
when genetically modified individuals and organisms travel.
Historical atrocities in Nazi Germany in the field of eugenics 7
experimentation on human subjects exemplify the failure of incon-

1. See Julia Black, Regulation as Facilitation:Negotiating the Genetic Revolution,
61 MOD. L. REV. 621 (1998).
2. See id.
3. Julie L. Gage, Government Regulation of Human Gene Therapy, 27
JURIMETRICS J. 200 (1987).
4. Thomas 0. McGarity, InternationalRegulation of Deliberate Release Biotechnologies, 26 TEX. INT'L. L.J. 423,424 (1991).
5. See id.
6. See id.
7. Sir Francis Galton introduced the term eugenics and defined it as "the studies of
the agencies under social control which may improve or impair the racial qualities of future generations physically or mentally." JOHN F. KILNER ET AL., GENETIC ETHICS: Do
THE ENDS JUSTIFY THE GENES? 27 (1997).
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sistent national regulation of genetic experimentation. The recurrence of such atrocities must be curbed by the creation and enforcement of uniform international regulatory standards for genetic experimentation. Furthermore, the emergence of widespread
testing of gene therapy illustrates the importance of universal
standards to prevent abuse in the application of this new technology. Such standards should also promote the changing direction of
preventative medicine and human health care.
Part II of this comment discusses the practice of genetic experimentation and its impact on all human beings. It provides a
brief overview of the basic elements of human genetics and genetic
disease. It also introduces the practice of genetic experimentation
as a therapeutic approach to disease control and prevention. It
then focuses on the history of abuses in the field of genetics with a
description of eugenics principles that gained international notoriety during the Second World War. Next, it discusses the reemergence of eugenics principles in modern applications of genetic
research, specifically in the application of germ-line genetic experimentation. It further explores the prospect of enhancement
gene alteration and the practice of selective reproduction. Finally,
it discusses the biological disparities that would arise from unequal
access to gene therapy treatments. Part III describes the current
status of international and national regulation of the use of modern, often experimental, medical technology on humans. It describes how these regulations can and are applied to the practice of
genetic experimentation. Part IV proposes a framework for uniform international regulation of human genetic experimentation
and briefly examines the issue of enforcement of any such international framework.
II. UNIVERSAL NATURE OF GENETICS AND THE IMPACT OF
GENETIC EXPERIMENTATION

A. Overview of Human Genetics and Disease
"When finally interpreted, the genetic messages encoded
within our DNA molecules will provide the ultimate answers to
the chemical underpinnings of human existence." 8 Deoxyribonu-

8. MAXWELL J. MEHLMAN & JEFFREY R. BOTKIN, ACCESS TO THE GENOME: THE
CHALLENGE TO EQUALITY 14 (1998).
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cleic acid (DNA) is the functional unit of biological inheritance. 9
The organization of DNA is fundamentally the same in all people. 10 This commonality of genetic composition is exemplified by
the fact that the genetic "blueprint" may be understood by refer11
ence to a limited number of genetic models.
Genes are composed of DNA, which control the synthesis of
proteins. 12 Proteins, in turn, serve as structural components of
13
various parts of the body, such as skin, bones, eyes and hair.
While "not every mutation causes disease" 1 4 or defects, mutations
15
in critical portions of important genes result in genetic disease.
Genetic diseases may arise spontaneously or as a result of environmental influences. 16 In any event, genetic diseases are responsible for much human suffering. 17 The ability to interpret genetic
messages would help explain not only how we function as healthy
human beings, but also the role of genetic factors in a multitude of
diseases "that diminish the lives of so many millions of people." 18
B. Benefits of Human Genetic Experimentation: The Promise of
Gene Therapy
The desire to find effective and permanent cures for genetic
diseases that impact so many lives has been the driving force behind much of gene therapy research. 19 "Gene therapy is the intentional alteration of genes in cells or tissues in such a way as to treat
or prevent an inherited disorder, or to make another pathological
condition more amenable to treatment. ' 20 Gene therapy introduces one or more genes into cells to treat, diagnose or prevent

9. See id.
10. Id. at 15.
11. See id.
12. M. A. SANTOS, GENETICS AND MAN'S FUTURE: LEGAL, SOCIAL, AND MORAL
IMPLICATIONS OF GENETIC ENGINEERING 9 (1981).

13. Id.
14. LEROY WALTERS & JULIE GAGE PALMER, THE ETHICS OF HUMAN GENE
THERAPY 15 (1997).

15. [d.
16. Id.
17. Id.
18. MEHLMAN, supra note 8, at 14.
19. SANTOS, supra note 12, at 15.
20. THE REPORT OF THE CATHOLIC BISHOPS' JOINT COMMITTEE ON BIOETHICAL
ISSUES, GENETIC INTERVENTION ON HUMAN SUBJECTS 6 (1996) [hereinafter BISHOP'S
COMMITTEE].
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diseases linked to genetic anomalies. 21 There are two types of gene
therapy: 1) somatic-cell and 2) germ-line. 22
1. Somatic-Cell Gene Therapy
Somatic-cell therapy involves manipulation of any cells that
do not have the potential to contribute to the genetic material of
offspring. 23 Many genetic disorders are treatable through somaticcell gene therapy.24 Various types of cancer and HIV infection/AIDS, 25 among other major diseases, are currently being targeted in somatic-cell gene therapy experiments. 26 Scientists anticipate using somatic-cell gene therapy in future treatments of
hemoglobin diseases and muscular dystrophy. 27
Critics of gene therapy contend that the use of somatic-cell
gene therapy is too expensive, noting that applications of current
techniques cost at least $100,000 per year per patient. 28 They also
assert that alternative drug treatments for individuals with genetic
diseases are improving, making costly somatic-cell gene therapy
techniques unnecessary. 29
Supporters of gene therapy theorize that it will someday be
used to prevent disease as routinely as immunizations and antibiotics are used today.30 One such visionary, Dr. W. French Anderson, has dreamed of the day when gene therapy will be used in a
practical way to relieve human suffering, "I'd like to go to Africa
with 10,000 vials and inject the gene to cure sickle-cell anemia."31
These ideals have likely motivated the extensive financing used to
advance somatic-cell gene therapy.

21. Charles F. De Jager, The Development of Regulatory Standards for Gene Therapy in the European Union, 18 FORDHAM INT'L L.J. 1303, 1307 (1995).
22. Id. at 1307-1308.
23. Id. at 1308.
24. Id. at 1310.
25. WALTERS, supra note 14, at 25.
26. Id. Other genetic diseases include: Cystic Fibrosis, Gaucher disease (type I),
SCID, Familial hypercholesterolemia, Alpha 1-antitrypsin deficiency, Fanconi anemia,
Hunter Syndrome (mild form), chronic granulomatous disease and purine nucleoside
phosphorylase (PNP) deficiency. Id.
27. Id. at 35-36.
28. Id. at 53.
29. Id.
30. Id.
31. Daniel Glick, A Genetic Road Map, NEWSWEEK, Oct. 2, 1989, at 46.
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2. Germ-Line Gene Therapy
Germ-line therapy involves manipulation of germ-line cells,
including gametes, zygotes and undifferentiated cells of embryos in
the early stages of development. 32 Germ-line gene therapy could
potentially be performed in sperm or egg cells, although current
33
studies involve only zygotes and pre-implantation embryos.
When an altered gene is added to a zygote or cells of a preimplantation embryo, it reproduces into a healthy gene in the zygote or embryo. 34 Essentially, germ-line therapy serves the function of "reducing the incidence of certain inherited diseases in the
human gene pool."' 35 Ideally, the successful practice of germ-line
therapy will treat genetic disease either before or shortly after con36
ception of the "patients" who are to be treated.
There are many reasons why germ-line therapy should be
pursued. First, it may be the only way to reach developing brain
37
cells or to prevent irreversible damage to the developing embryo.
Second, although more expensive to administer than traditional,
and even somatic-cell gene therapy, the long-term benefits far
outweigh the increased cost. 3 8 From a medical and public health
perspective, if germ-line therapy is applied both to affected individuals, as well as those carriers of defective genes who do not
manifest symptoms of disease, it would decrease the occurrence of
genetic disease within the human gene pool. 39 In the long run, the
benefit to the human race is immeasurable.
As illustrated above, the benefits of germ-line gene therapy
are many. They suggest that the use of this type of genetic experimentation should remain a viable field of scientific research.
The development of germ-line gene-therapy could be placed
among the "[m]yriad biotechnology applications [with] the potential to alleviate some of the most pressing problems facing the
global community, as well as to reduce dramatically human suffering and to improve the quality of life, particularly in the develop-

32.
33.
34.
35.
36.
37.
38.
39.

De Jager, supra note 21, at 1308.
WALTERS, supra note 14, at 62.
Id.
Id. at 63.
Id. at 74.
Id. at 80-81.
Id. at 81.
See id.
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ing world." '40
C. PotentialDangers of Human Genetic Experimentation
The great potential for benefit of germ-line therapy, however,
must be balanced against the potential for abuse. "[T]he global
community ought to coordinate and augment traditional treaty regimes" 41 to ensure the greatest degree of medical benefit with
minimal risks of abuse in the experimental process.
1. History of Abuses in Genetics: The Principles of Eugenics
Experimentation in the field of genetics was introduced to the
world through the reported atrocities of Nazi Germany's experimentation with eugenics. 42 In 1883, British biologist, Sir Francis
Galton, introduced the term eugenics and defined it as "the studies
of the agencies under social control which may improve or impair
the racial qualities of future generations physically or mentally. '43
Galton sought to "maximize intelligence and prevent feeblemindedness... [by] advocat[ing] marital arrangements to breed a highly
intelligent group of men for a number of generations. '"44
The Nazi practice of eugenics was termed "racial hygiene" by
the German social Darwinist, Alfred Ploetz. 45 He attacked traditional medicine as "medical practice that helps the individual but
endangers the race by allowing individuals, who would not have
otherwise survived, to live and reproduce themselves. '46
At the center of Hitler's policies were programs "aimed at
ending racial deterioration." 47 The government passed the Sterilization Act, intending to prevent "hereditary taint."'48 The Act
called for sterilization in cases of "'congenital mental deficiency,'
schizophrenia, 'madness,' congenital epilepsy, Huntington's chorea, blindness, deafness,.. .serious disability.. .and 'chronic alco-

40. Sean D. Murphy, Biotechnology and InternationalLaw, 42 HARV. INT'L L.J. 1, 47
(2001).

41.

Id. at 49.

42.

See KILNER, supra note 7, at 27.

43.
44.
45.
46.
47.

Id. at 25.
Id. at 26.
See id.
Id.
Id. at 27.

48.

ARTHUR ROGERS & DENIS DURAND DE BOUSINGEN, BIOETHICS IN EUROPE 26

(1995).
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hol[ism]."' 49 An explanatory text attached to the Act states that
"German people 'cannot afford the luxury of allowing the person
concerned to choose whether or not to be sterilized. ' ' 50 Between
1937, approximately 400,000 sterilizations took place in
1934 and 51
Germany.
The practice of eugenics, however, was not limited to Nazi
Germany. 52 Switzerland, for example, passed the first European
sterilization law permitting sterilization of those likely to produce
"degenerate offspring." 53 Before 1930, 15,000 individuals in the
United States were sterilized in accordance with laws passed in
twenty-eight states, which allowed for sterilization of the mentally
ill and criminally insane to discourage "socially disadvantageous"
breeding. 54 By 1939, 30,000 people in the United States were sterilized in the name of eugenics. 55 Towards the end of the Second
World War, however, sterilization practices in the United States
of sterilization laws was aldropped significantly. Enforcement
56
most nonexistent in the 1950s.
2. Resurgence of Eugenics Principles
Some critics argue that human beings have a right to inherit a
genome that has not been artificially changed. 57 Critics of germline therapy, specifically human rights advocates, argue that "human beings have a moral right to receive from their parents a genetic patrimony that has not been subject to artificial tampering."' 58 This is consistent with arguments against germ-line therapy
that contend it invests in a small group of human beings too much
control over the evolution of the human race in the reshaping of
the genetic code.59 These objections to germ-line therapy reflect a
of DNA that shapes the
strong resistance to artificial manipulation
60
genetic traits of future generations.

49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.

Id. at 27.
Id. at 26.
See KILNER, supra note 7, at 27.
See id.
Id.
Id.
Id.
Id. at 28.
BISHOP'S COMMrITEE, supranote 20, at 31.
WALTERS, supranote 14, at 84.
Id.
See id.
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Others argue that germ-line therapy revives principles of Nazi
racial hygiene programs that would allow government leaders to
attempt to produce "a class of superior human beings. ' 61 The byproducts of past eugenics abuses by the national socialist regime
have "placed a permanent blot on the reputation of medical science, while providing irrefutable evidence of the consequences of
a policy based on the selection of the fittest. '62 These criticisms,
and the fear of future abuses, have obvious merit. 63 Fear of the
powerful tool of gene therapy, however, should not stand in the
64
way of its immense potential for disease control and prevention.
With appropriate, enforceable regulatory standards for the application of germ-line gene therapy, this developing technology may
serve as one of the most positive, significant medical advances in
history.
a. Enhancement Genetics
One highly criticized form of genetic experimentation does
not involve correcting abnormal genes or curing disease. 65 Enhancement genetics works to "amplify 'normal' genes in order to
make them 'better."' 66 There are currently five types of enhancements that are products of genetic engineering. 67 These include:
size (growth hormone therapy may take the form of germ-line or
somatic-cell gene therapy), 68 sleep (gene therapy may be used to
alter genes that encode for proteins that regulate the sleepcycle), 69 aging (experiments have shown that mutating a single
gene (the age-1 gene) in non-human organisms has prolonged life
71
by 40-60%), memory70 and aggression.
"Genetic enhancement raises a host of ethical, legal, and social questions." 72 Some contend that it is not enough to merely
distinguish between genetic experimentation for therapy and for
61. Id.
62. ROGERS, supra note 48, at 30.

63.
64.
65.
66.
67.
68.
69.
70.
71.
72.

See id.
Id. at 85.
MEHLMAN,

supra note 8, at 35.

Id.

supra note 14, at 101.
Id. at 101-102.
Id. at 102-103.
Id. at 104-106.
Id. at 106-107.
Maxwell J. Mehlman, How Will We Regulate Genetic Enhancement? 34 WAKE
FOREST L. REV. 671, 673 (1999).
WALTERS,
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genetic enhancement in determining whether enhancement therapy is ethical. 73 Instead, the argument continues, where enhancement is involved, experimentation should be deemed "morally
wrong if done with improper motives." 74 The fact that genetics
may be used as a vehicle to advance improper motives, however,
must not, in and of itself, render attempts at physical or mental
75
enhancement altogether immoral.
Individuals are constantly attempting to enhance their appearance and their minds through unnatural methods. 7 6 These
methods are not more ethical simply because they do not employ
genetics to achieve the desired results.7 7 Accordingly, a focus on
the intent of the therapy, the degree of voluntariness (or parental
consent) and motivation are more appropriate factors for determining when enhancement therapy is ethically acceptable. 7 8 Using
these criteria to determine the appropriateness of the gene therapy
would better protect the public. For example, should a national
leader seek to utilize genetic enhancement to create a uniform,
"superior race," such motivation would be deemed unethical since
79
it is motivated by eugenics principles.
b. Unnatural Selection
Many worry that increased knowledge of genetic information
increases the potential for abuses of the type that existed during
the early days of eugenics practice. 80 "The power of the information to be gained from [genetic] mapping and sequencing projects
raises concerns about how it will be used." 81 "The only way to ensure that history does not repeat itself is for the scientific and
medical communities to remain constantly vigilant for abuses of
'
genetics. "82
Today, eugenics is practiced in a subtler manner. Such practices that reflect eugenics principles, absent the overtly unethical
appearance of historical eugenics, include sperm and egg banks

73.

KILNER, supra note 7, at 189.

74.
75.
76.
77.
78.
79.
80.
81.
82.

Id.
See id.
See id.
See id.
See id. at 188.
See id. at 189.
Id. at 29.
Id. at 25.
Id.

96
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such as the "Repository for Germinal Choice."' 83 Established in
the 1950s, the sperm bank "offer[ed] artificial insemination using
sperm donated by 'superior' persons." 84 The ideal behind this particular bank was to "decrease the 'genetic load'.. .of potentially le'85
thal genes in the human gene pool."

Another example of applied modem eugenics principles is
genetic counseling. 86 The goals of genetic counseling are not to
create a uniform race or to specifically alter the gene pool in any
particular manner. 87 Genetic counseling does, however, have the
ultimate effect of influencing potential parents in their decision to
have children based on the possibility of defective genetic traits in
their offspring. 88 This form of eugenics is more properly described as laissez-faire eugenics. 89 This is an appropriate description for genetic counseling as one of the goals "is to enable families in which a genetic disorder exists to choose the courses of
action that are best for them, and to make choices while taking
into consideration their own values and beliefs in both reproductive decision-making and follow-up care." 90
3. Inequitable Access to Medical Technology
a. Potential for Decline in Genetic Diversity
"There are long-term concerns about whether the widespread
use of genetically modified products could accelerate the decline in
global biological diversity." 91 In order for individuals to gain access to genetic technology, there must be an adequate supply, it
92
must be affordable and individuals must be informed about it.
Access to traditional modes of health care, however, has historically been wealth-based. 93 This has caused inequities on both domestic and international levels. 94

Given the current social and

83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.

Id. at 29.
Id.
Id.
Id.
See id.
See id. at 147-148.
See id.
Id. at 148.
Murphy, supranote 40, at 48.
MEHLMAN, supra note 8, at 55.
Id. at 86.

94.

See, e.g., PHILIP KITCHER, THE LIVES TO COME 324 (1996).
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economic disparities among social classes, creating unequal access
to genetic experimentation may potentially create a greater separation between the rich and the poor.
b. Depletion of Resources for the Treatment of Other Diseases
A major concern for genetic research worldwide is prioritizing
the allocation of limited medical resources. 9 5 "Everyone has the
right to enjoy the benefits of scientific progress and its applications." 96 Essentially, the question is whether it is ethical to allocate medical research resources to treat diseases traceable to single
genes, or whether those resources should be used to treat more serious conditions prevalent in third and fourth world nations. 97 Unfortunately, the global trend has been for affluent governments to
provide large funding for research to treat relatively uncommon
genetic disorders, while providing comparatively insufficient funds
to nations where "millions of children die of malaria." 9 8 The disparity among nations in funding and the focus of genetic research
should be considered as international regulation of genetic research develops.
III. THE CURRENT STATE OF REGULATORY LAW APPLICABLE TO
GENETIC EXPERIMENTATION

Genetic research has a global impact. As such, "regulation
has an important role to play.., in facilitating the integration of
the wide range of views as to the appropriate course that the technology and its regulation should take." 9 9 In an attempt to meet
this goal, and to protect this technology from abuses, international
guidelines have been established in the form of the Nuremberg
Code °0 and the Helsinki Declaration.1 0 1 These guidelines show

95. See id.
96. Vienna Declarationand Programme of Action, U.N. GAOR, 48th Sess., pt. I, 22d
mtg. 21.7.1.(a)(i-vi), U.N. Doc. A/CONF.157124 (1993).
97. Id.
98. Id.
99. See Black, supra note 1,at 621.
100. 2 TRIALS OF WAR CRIMINALS BEFORE THE NUREMBERG MIL. TRIBUNALS
UNDER
CONTROL
COUNCIL Law No.
10, 181-182 (1949)
available at
http://ohsr.od.nih.gov/ Nuremberg.php3 [hereinafter Nuremberg Code].
101. World Medical Association, Declaration of Helsinki, reprinted in THE NAZI
DOCTORS

AND

THE

NUREMBERG

CODE:

HUMAN

RIGHTS

IN

HUMAN

EXPERIMENTATION 333-336 (George J. Annas & Michael A. Grodin eds., 1992) [hereinafter Helsinki].

Loy. L.A. Int'l & Comp. L. Rev.

[Vol. 24:87

an appreciation for "the need for human experimentation while
accepting that this can only be accomplished at the expense of
some of the subjects' right to self-determination. ' 102
A number of nations that actively regulate the practice of
human subject experimentation have implemented and attempted
to expand the principles in the Helsinki Declaration. 10 3 This section discusses the focus and effect of international, European and
U.S. regulatory standards for genetic experimentation on humans.
A. Scientific Experimentation on Humans: The Nuremberg Code
and Helsinki Declaration
International declarations arose in response to abuses of scientific experimentation on human subjects. 10 4 These declarations
set forth standards for maintaining respect for dignity and bodily
autonomy in the practice of human subject experimentation. 10 5
The Nuremberg Code was the first set of international guidelines
developed and implemented. 10 6 The Nuremberg Code is the
product of the trials of twenty doctors who "knowingly agreed to
dehumanize medicine by relegating individuals to the status of
mere 'guinea pigs.' 10 7
During the Second World War, these doctors in Nazi Germany conducted countless experiments, many in the field of genetics, that resulted in the often violent, painful and dehumanizing
deaths of millions of unwilling human test subjects. 10 8 After the
Second World War, the realization of the grave potential of human
rights violations in the name of scientific experimentation became
evident. 10 9 This realization catalyzed the first major international
debates on medical ethics. 110 The Nuremberg Code emphasized
the importance of voluntary consent of the subject, the need for a
beneficial purpose of the experiments on society, the limited risk

102. J. K. MANSON & R. A. MCCALL SMITH, LAW AND MEDICAL ETHICS 349, 350
(1994).
103. See JOHN ZIMAN ET AL., THE WORLD OF SCIENCE AND THE RULE OF LAW: A
STUDY OF THE OBSERVANCE AND VIOLATIONS OF THE HUMAN RIGHTS OF SCIENTISTS
IN THE PARTICIPATING STATES OF THE HELSINKI ACCORDS 1 (1986).

104. Id.
105.

ROGERS,

106.
107.
108.
109.
110.

Id.
Id.
Id. at 68.
See id.
Id. at 69.

supra note 48, at 69.
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of harm to the research subject and the freedom of the subject to
bring the experiment to an end. 111
The Helsinki Declaration was another result of the abuses
discovered after World War 11.112 Part of the larger Helsinki Accord, the Helsinki Declaration was drafted by the World Medical
Association in 1964 and signed as part of the Accord by the leaders of thirty-five nations in 1975.113 The Helsinki Declaration,
much like the Nuremberg Code, attempts to protect human subjects of biomedical research. 114 It goes further than the Nuremberg Code, however, by establishing guidelines for non-therapeutic
clinical research, 1 15 providing additional protection for subjects
who would not receive any direct therapeutic benefit from the ex116
periments.
Similarly, neither the Nuremberg Code nor the Helsinki Declaration imposes legal obligation on the signatory nations.1 17 The
Helsinki Accord specifically states that "the text 'is not eligible for
registration under article 102 of the Charter of the United Na118
tions"' indicating that "it is not a binding international treaty."
Nevertheless, while the two documents do not directly carry with
them the full force of law, their very existence represents world
leaders' recognition of the need for ubiquitous standards of biomedical research that serve to protect individuals on an international level. 119
B. NationalLaw On Genetic Experimentation
Most nations currently regulate human genetic experimentation by defining acceptable practices for human subject experimentation. 120 This approach seems appropriate since, to date, all
practices of genetic experimentation on humans are in the experimental phase. 121 The European Communities and United States
draw their regulations and the policies behind them from the prin-

111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.

Nuremberg Code, supranote 100.
See Helsinki, supra note 101, at 336.
ZIMAN, supra note 103, at 1.
Helsinki, supra note 101, at 336.
Id.
Id.
ZIMAN, supra note 103, at 1-2.
Id.
See id.
Id. at 10.
Id.
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ciples of the Nuremberg Code and the Helsinki Declaration. Another similarity between the European and U.S. laws is that nei122
ther expressly addresses the practice of germ-line gene therapy.
U.S. and European Communities laws differ, however, in that "the
trend in the United States has been to ease the regulatory burden,
[whereas] the emphasis in the European Communi[ties]... has
123
been to tighten and harmonize regulatory standards."
1. Regulation of Genetic Experimentation in the European
Communities
The strongest gene therapy regulations in the European
Communities involve good clinical practice for medical drug trials
on human subjects. 124 These regulations take the form of a Council Directive on "the approximation of the laws, regulations and
administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use." 125 Based primarily on
the Helsinki Declaration, the regulations passed by the Commission of European Communities seek to protect human rights and
the dignity of the human being during research in biology and
medicine. 126 The regulations serve several distinct functions, each
of which are designed to protect the human subject from different
127
sources of harm.
First, the regulations protect the subject from adverse effects
of experimental treatment by requiring toxicology tests prior to
clinical trials. 128 Accordingly, any new drug, including gene therapy drugs, must be tested for toxicity on live subjects (i.e., animals)

122. See id. at 40.
123. Colleen K. Ottoson, Comment, Regulation of Biotechnology in the European
Community: How Twelve Nations Are Transforminga Global Industry, 16 MD. J. INT'L L.
& TRADE 255, 257 (1992); See FDA Head of Biologics Will Accelerate Review Time Table, BIOTECHNOLOGY NEWSWATCH, Mar. 16, 1992, at 1; AUDREY WINTER ET AL.,
BUREAU OF NATIONAL AFFAIRS, EUROPE WITHOUT FRONTIERS: A LAWYER'S GUIDE

272-77 (1989).
124. See Council Directive 2001/20/EC, 2001 O.J. (L 121) 34.
125. Id.
126. The text specifically states, "Whereas... (2) [t]he accepted basis for the conduct
of clinical trials in humans is founded in the current revision of the Declaration of Helsinki
and the Council of Europe Convention for the protection of Human Rights and dignity of
the human being with regard to the application of biology and medicine." Id.
127. Id.
128. Id.
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prior to human exposure at the clinical trial. 129 This requirement
is consistent with the spirit of the Helsinki Declaration. 130 Like
the Declaration, it balances the protection of individual health
with the interest in immediate advancement of medical technol13 1
ogy.
Second, ethics committees must screen clinical trials before
they may be initiated. 1 32 This screening process essentially promotes the principles of the Nuremberg Code 13 3 and the Helsinki
Declaration. 134 The committees are comprised of disinterested individuals who can assess the benefit to both the individual patient
and society and the risks of subjecting a human being to the clinical trials.13 5 This committee evaluation is particularly significant in
light of prior abuses of genetic experimentation, and specifically to
13 6
avoid an unchecked reemergence of eugenics practices.
Finally, the European laws provide for the protection of personal-data. 1 37 Ideally, this protection prevents the release of private medical information about the human subject involved in the
trials. Maintaining the anonymity of the subjects prevents potential insurance or employment discrimination associated with ge138
netic disease.
Unfortunately, while these regulations focus primarily on the
impact of experimentation on the individual, they do not address
the problem of equal access to experimental procedures. 139 They
also fail to encourage innovations in developing biotechnology, as
evidenced by the European Communities' opposition to the development of germ-line therapy, whose long-term impact is unknown. 14° These deficiencies, however, are not unique to Euro-

129. Id.
130. See Helsinki, supra note 101, at 333.
131. See Council Directive 2001/20/EC, 2001 OJ. (L 121) 34.
132. See id.
133. See Nuremberg Code, supra note 100.
134. See Helsinki, supra note 101.
135. See id.
136. See KILNER, supra note 7, at 27.
137. Council Directive 2001/20/EC, 2001 O.J. (L 121) 34.
138. See id.
139. See id.
140. Id. In particular, the European Parliament's Commission on Civil Liberties and
Internal Affaires explicitly states, "Fearful of the dangers of a new eugenics movement,
[the European Union and its Member States oppose] any moves to permit experiments
which could result either directly or indirectly in the modification of heritable genetic
characteristics (germ-line genetic engineering) or in the production of geneticallyenhanced human beings or human research models by cloning or other equivalent tech-
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pean law. National regulations patently fail to address the farreaching and long-term impacts of modem research techniques.
These 1 deficiencies are equally prevalent in U.S. medical research
14
law.
2. Regulation of Genetic Experimentation in The United States
a. Federal Regulations
U.S. regulations 142 seek to protect human autonomy and dignity as suggested by the Nuremberg Code 143 and the Helsinki Declaration. 144 The U.S. Code of Federal Regulations (Federal Code)
emphasizes the importance of patient safety and bodily autonomy. 145 These regulations are primarily enforced by Institutional
Review Boards (IRBs). 146 IRBs are established by research institutes and are comprised of scientists, ethicists and members of the
general public to evaluate the specific experimental protocol for
institutes conducting research to ensure that the intent of the Federal Code is met.147 The IRB has the power to amend or even to
seek the termination of148a particular protocol if it fails to comport
with the Federal Code.
The Federal Code protects bodily autonomy through the requirement of informed consent. 149 "An IRB shall require documentation of informed consent or may waive documentation in accordance with § 46.117." 150 Informed consent means that the

niques." Resolution on Respect for Human Rights in the European Union (1997), A40468/98, 1999 OJ. (C 98) 279.
141. See 45 C.F.R. §§ 46.101-46.409 (2000).
142. See id.
143. See Nuremberg Code, supranote 100.
144. See Helsinki, supra note 101, at 333-336.
145. See §§ 46.101-46.409.
146. See id.
147. See id.
148. § 46.109. This section specifically calls for an IRB that "shall review and have authority to approve, require modifications in (to secure approval), or disapprove all research activities covered by this policy." Id.
149. Id.
150. Id. at § 46.109(c). § 46.117 provides for waiver of informed consent if the IRB
finds "(1)That the only record linking the subject and the research would be the consent
document and the principal risk would be potential harm resulting from a breach of confidentiality. Each subject will be asked whether the subject wants documentation linking the
subject with the research, and the subject's wishes will govern; or (2) That the research
presents no more than minimal risk of harm to subjects and involves no procedures for
which written consent is normally required outside of the research context." Id. at §
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potential human subject is informed of the risks involved in taking
part in the trial. 15 1 It also requires the subjects to be informed of
his or her freedom to suspend or halt the trial at any time. 15 2 Informed consent helps guarantee that the human subject is in control of personal health decisions. 15 3 The emphasis on informed
consent arose out of past eugenics abuses, such as mandatory, nonconsensual sterilizations of individuals considered not worthy to
breed. 1 54 The hope is that informed consent will lessen the risk of
future abuses in the experimental process, and, in particular, in the
15 5
manipulation of the human genome.
The Federal Code also emphasizes that research practices
must minimize the health risk to the test subject. 156 It provides
that subjects may participate in experimental drug trials only when
it poses minimal risk to the health and safety of the subject. 157 For
a test to receive IRB approval it must minimize "[r]isks to subjects... [by] (i) using procedures which are consistent with sound
research design and which do not unnecessarily expose subjects to
risk, and (ii) whenever appropriate, by using procedures already
being performed on the subjects for diagnostic or treatment purposes."' 15 8 Non-beneficial treatment is also allowed under both the
Federal Code 15 9 and the Helsinki Declaration. 160 The question
remains, however, whether the current regulations are sufficiently
161
effective to regulate the newer experimental gene therapy trials.
b. Diminished Authority of United States Regulatory Agencies
In October of 1974, the National Institutes of Health (NIH)
established the Recombinant DNA Technology Committee
(RAC) "in response to public concerns regarding the safety of

46.117(c).
151. See id. at § 46.117.
152. See id. at § 46.116.
153. See id.
154. See KILNER, supra note 7, at 27.
155. See id.
156. See 45 C.F.R. § 46.116(d)(1) (2000).
157. See id.
158. Id. at § 46.111(1).
159. See id.
160. The Helsinki Declaration provides a separate four-part section of guidelines entitled "Non-therapeutic biomedical research involving human subjects (non-clinical biomedical research)." Helsinki, supra note 101.
161. See
YVONNE
M.
CRIPPS,
CONTROLLING
ENGINEERING AND THE LAW 81 (Praeger Publishers 1980).
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manipulation of genetic material through the use of recombinant
deoxyribonucleic acid (DNA) techniques. ' 162 Regulatory control
over human biotechnology, however, has since become "fragmented, both jurisdictionally and substantively. 1 63
Since its inception, the RAC, "which includes scientists, lawyers, ethicists, and consumers," has lost much of its regulatory potency. 164 For example, RAC membership has been reduced from
twenty-five members to only fifteen, and it no longer has the authority to approve or block recombinant DNA experiments involving gene transfer. 165 Rather, the Food and Drug Administration
(FDA) retains statutory authority to approve or disapprove gene
transfer experiments; 166 however, "the FDA cannot regulate nor
directly oversee all the innovative work being carried out in academic institutions." 167 Thus, when researchers submit a proposed
human gene transfer protocol to the NIH, they must simultaneously submit an application for investigational new drugs to the
FDA for approval. 168 These rigorous and often duplicative standards are necessary due to "concerns that the FDA [alone] cannot
adequately address the ethical implications of novel gene therapy
investigational new drugs." 169
The Federal Code, 170 like the European Communities regulations, 171 focuses primarily on the protection of human life. The
IRBs, who are ultimately responsible for deciding whether or not
an experiment may go forward, do not inquire into the societal or
cultural impact of performing new experiments. 172 Rather than

162. Judith E. Beach, The New RAC: Restructuring of the National Institutes of
Health:Recombinant DNA Advisory Committee, 54 FOOD & DRUG L.J. 1,49 (1999).
163. Dorean M. Koenig, The Regulation of Modern Biomedical Techniques, 38
DEPAUL L. REV. 1013 (1989).
164. Beach, supra note 162, at 49.
165. See id.
166. See id.; See also Federal Food, Drug and Cosmetic Act, Pub. L. No. 75-717, § 505,
52 Stat. 1040, 1052 (1938) (codified as amended at 21 U.S.C. § 355 (1994)); 21 C.F.R. pt.
312 (1998).
167. Phillip D. Noguchi, From Jim to Gene and Beyond: An Odyssey of Biologics
Regulation, 51 FOOD & DRUG L.J. 367, 372 (1996).
168. See Beach, supra note 162, at 51.
169. Id. at 50.
170. See 45 C.F.R. §§ 46.101-46.409 (2000).
171. See Council Directive 2001/20/EC, 2001 O.J. (L 121) 34.
172. In fact, § 46.111 specifically states, "The IRB should not consider possible longrange effects of applying knowledge gained in the research (for example, the possible effects of the research on public policy) as among those research risks that fall within the
purview of its responsibility. § 46.111(a)(2).
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protecting the general population, the Federal Code regulates the
impact of experimental procedures on individuals. 173
These efforts, however, should not be too harshly criticized.
Regulatory agencies are placed in the competing role of both regulator and promoter of developing genetic technologies. 174 As
promoters, these agencies seek "to maximize successful projects
and scientific breakthroughs" leaving them "no incentive to enforce any regulation that might prevent the science from moving
forward. ' 175 As regulators, however, the agencies "are supposed
to be careful and conservative," erring on the side of safety. 176
Where one agency serves these dual functions "doing both satis17 7
factorily may be impossible."

IV. A

FRAMEWORK FOR INTERNATIONAL REGULATION OF THE
SCIENCE OF GENETIC EXPERIMENTATION

Because human gene therapy has such far-reaching potential
benefits for preservation and maintenance of human health, the
practice must be both protected and guarded against. 17 8 "The possibility of widespread industrial application of genetic engineering
is not remote." 1 79 Furthermore, biotechnology as a whole is a
"strategic industry" with significant regulatory deficiencies. 18 0
Therefore, "instead of attempting to fit regulation of gene therapy
into the existing framework, it may be better to... ask what regulatory framework would be best now, yet be flexible enough to
18 1
change as the industry grows."'
The regulation of gene therapy must be as broad as the practices of science and technology. Because science and technology
can potentially reach anywhere in the world, regulations must be
equally expansive. 1 82 They must encourage responsible develop-

173. See §§ 46.101-46.409.
174. Gregory A. Jaffe, Inadequacies in the Federal Regulation of Biotechnology, 11
HARV. ENVTL. L. REV. 491,529 (1987).
175.

Id.

176. Id.
177. Id.
178. See e.g., CRIPPS, supra note 161, at 9-19.
179. Stevan M. Pepa, InternationalTrade and Emerging Genetic Regulatory Regimes,
29 LAW & POL'Y INT'L Bus. 415,418 (1998).
180. Judith A. Cregan, Light, Fast, and Flexible: A New Approach to Regulation of

Human Gene Therapy,32 MCGEORGE L. REV. 261,284 (2000).
181. Id.
182. See id.
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ment of technologies without significantly detracting resources
from traditional and more accessible forms of disease treatment
and prevention. 183 Ultimately, the task of regulating genetic experimentation falls on the international community. It is only
through international regulation that these technologies will reach
their potential while imposing minimal adverse consequences for
184
the world community.
A. A ProposedFrameworkfor InternationalRegulation of
Genetic Research
1. General Concepts of International Regulation of Medical
Technology
Any law passed "specifically for the purpose of controlling
genetic [experimentation] should aim toward the establishment of
a unified system that would, to the fullest extent possible, govern
every facet of the technology.' ' 185 For international law to be universally accepted and effective, however, it must be narrowly tailored to address only those issues that are common to all individuals impacted by the research. 186 Since social norms differ from
nation to nation, international regulation must focus on preventing
negative global impact, while respecting preexisting national laws
that reflect values and ideals unique to each society. 187 This approach would serve the dual function of creating uniform standards for the common protection of all human beings while, at the
same time, allowing nations to protect their sovereignty by preserving local regulations. This would also encourage the application and enforcement of both the international and domestic regu188
lations.
2. International Cooperation
"In spite of the fact that all states are dependent on a shared
environment, the international community has, in the past, been
slow to recognize the need to regulate the harmful effects of new

183. See id.
184. See id
CRIPPS, supra note 161, at 81.
186. See id. at 81.
187. See id. at 126.
188. See id. at 125.

185.
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technologies." 18 9 The formation of a "transnational forum on biotechnology [such as genetic experimentation] ... could... be instrumental in achieving consensus on a coherent and effective legal
regime that addresses concerns with transnational biotechnology
and balances the tremendous opportunities of biotechnology
190
against its potentially severe and adverse transnational effects."'
These international committees should be formed out of different
interest groups "in order to balance interests with regard to [genetic] biotechnology.' 19 1 The committees would consist of representatives, such as scientists, lawmakers and ethicists that monitor
or region that practice genetic
and enforce the laws of each 19nation
2
humans.
on
experimentation
The national representatives would have a number of reporting duties. First, they would report to the World Heath Organization (WHO) and to each other on the current status of genetic research and "information on the physical and mental health" of the
Furthermore, national representatives
nation's population. 193
would provide information focusing on the current state of research in human genetics to reduce risks of delaying notification of
"perceived dangers" until after their manifestation. 19 4 Free disclosure of such information would also prevent any one nation from
advancement of, and potential
falling significantly behind in the
19 5
access to, genetic technology.
Second, information provided to the WHO and each of the
represented nations would include proposals for new innovations
in human genetic experimentation. 19 6 Disclosure of new proposals
would serve two necessary functions. First, disclosure would educate less technologically advanced populations in the latest tech-

189. Id. at 124.
190. Sean D. Murphy, Biotechnology and InternationalLaw, 42 HARV. INT'L L.J. 47,
49(2001).
191. Valerie Szczepanik, Regulation of Biotechnology in the European Community, 24
LAW & POL'Y INT'L Bus. 617, 642 (1993).

192. See, e.g., 45 C.F.R. §§ 46.101-46.409 (2000).
193. These reporting guidelines are similar to those proposed in the Guidelines Regarding the Format and Contents of Reports to be Submitted States Parties under Articles
16 and 17 of the International Convention on Economic, Social, and Cultural Rights. See
BRIGIT C.A. TOEBES, THE RIGHT TO HEALTH AS A HUMAN RIGHT IN INTERNATIONAL

LAW 367 (Intersentia-Hart 1999).
194. See CRIPPS, supra note 161, at 124.
195. See MEHLMAN, supra note 8, at 55, 87.
196. See CRIPPS, supra note 161, at 82.
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nologies. 197 Knowledge of the existence of such technologies is essential if developing nations are to be given an opportunity to utilize them. 198 Second, disclosure would provide a more thorough
evaluation of the global implications of the new technologies. 199
Finally, the representatives would be required to include reports on the efficacy of current domestic regulation, as well as recommendations for more effective implementation and enforcement of national laws. 200 Shared information on the efficacy of
domestic health law would encourage consistency in the applica201
tion of these laws worldwide.
3. New Proposals
Before new gene therapy protocols can be approved, the organization seeking to implement the protocol would have to submit a report to local domestic regulatory bodies. 202 The report
would outline the risks and benefits of the experiments and show
that the protocol adheres to national guidelines. 20 3
If the proposal involves novel forms of genetic experimentation, it is submitted to the international committee for review.20 4
The proposal would be reviewed to insure it is consistent with international regulations. 20 5 Presentation to the international committee would provide an additional safety net; protecting against
domestic laws or regulations that may fail to recognize that "all
197. See MEHLMAN, supra note 8, at 55, 87.
198. See id.
199. See id.
200. See CRIPPS, supra note 161, at 125.
201. See TOEBES, supra note 193, at 154.
202. See CRIPPS, supra note 161, at 82.
203. CRIPPS, supra note 161, at 82-83. This system of national approval was recommended by the working party of New Zealand which proposed that a national committee
adjudicate on novel genetic techniques including: "(a) any procedures involving the combination of DNA or RNA [Ribonucleic Acid] molecules of different biological origin by
means that overcome natural barriers in mating and recombination, to yield molecules
that can be propagated in some host cell and the subsequent study of such molecules; (b)
any procedures involving the combination of chemically or enzymatically prepared copies
of DNA or RNA molecules ... that can be propagated in some host cell, and the subsequent study of such molecules; (c) with the specific exceptions.. .the fusion of animal,
plant, fungal, or bacterial cells inter-specifically by whatever means, leading to the formation of cells or complete organisms with novel genetic constitution." Id.
204. TOEBES, supra note 193, at 154. This model is based on reporting practices for
the ESC wherein "[n]ational reports are.. .sent to the Secretary General of the Council of
Europe at two-yearly intervals concerning the application of the provisions.. .that the
State party has 'accepted."' Id.
205. See CRIPPS, supranote 161, at 82-83.
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states are dependent on a shared environment. ' 20 6 It would standardize the research 2consistent
with the Nuremberg Code 207 and
08
Helsinki Declaration.
Since the human gene pool "represents the collection of genes
carried by all humans alive in a given population," 20 9 any new proposal would also have to include an analysis of the impact of the
protocol on the current model of the human genome to determine
210
the negative consequences of the therapy for future generations.
"Even proponents of germ-line manipulation recognize that a
number of safeguards must be in place before germ-line technology will be ready for use in humans." 211 The current model of the
human genome serves as the basis not only for genetic equality,
but also of the human species. 212 The impact of altering the model
would disrupt research efforts that are based on the current model.
New therapeutic protocols for genetic experiments impose
potentially unpredictable, and possibly detrimental, consequences
to the human race when an altered genome reacts to the natural,
global environment. 213 One precaution that has been proposed
would require researchers to "post bonds and prepare plans for
cleanup in the event of inadvertent dispersal" of genetically altered materials into the environment. 214 This measure may be implemented on an international scale requiring regional sponsors of
proposed research to post bonds. 215 Analysis of the impact of genetic experimentation is likely the most complicated function of
the international committees.
4. Approval of the New Proposals
After assessing the impact of the protocol on the human genome, the international committee would approve, disapprove or
seek modification of the protocol. 216 A unanimous approval
206. See CRIPPS, supra note 161, at 124.
207. See Nuremberg, supra note 100.
208. See Helsinki,supra note 101.
209. Robert B. Wilson, EnvironmentalRegulation of the Human Gene Pool as a Genetic Commons, 5 N.Y.U. ENVTL. L.J. 833,833 (1996).
210. Id. at 842.
211. Id.
212. See MEHLMAN, supra note 8, at 15.
213. See, e.g., Wilson, supra note 209, at 842.
214. Valerie M. Fogleman, Regulating Science: An Evaluation of the Regulation of
Biotechnology Research, 17 ENVTL L. 183,269 (1987).
215. See CRIPPS, supra note 161, at 84.
216. See id.
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would be highly unlikely.217 Therefore, in order to advance genetherapy technology, a unanimous approval should not be required.
Rather, a supermajority should suffice to assure protection of the
human genome, while encouraging genetic research through new
experimental technologies.218
The adverse consequences of inadequate medical resources
would suggest that the international conference should provide
equitable access to the technologies. 219 Knowledge of the existence of the technologies is a starting point.220 This knowledge
would be facilitated by the reports of the representatives at the international conference. The committee would also have to find a
way to equally distribute approved genetic experimentation technology to different regions of the world. 221 This equal access to
genetic experiments and technology would ensure that "products
of the technology of genetic [experimentation do not] traverse national boundaries and. . .upset the ecological balance in distant
222
states."
B. Enforcement
The enforcement of any international regulation has been historically difficult.223 "The difficulties involved in enforcing judgments increase geometrically when the legal systems of two or
more countries are implicated. ' 224 Difficulties in implementation,
however, cannot hinder efforts to protect individual human dignity
and autonomy. Hopefully, avoiding the atrocities of Nazi Germany's eugenics practices is a goal of national leaders. Such
awareness of and protection against eugenics and uninformed consent are integral to maintaining the dignity and autonomy of indi5
22
viduals around the world.

V. CONCLUSION

Human genetic experimentation's potential for both benefit
217. See id. at 85.
218. See id. at 81.
219. See MEHLMAN, supranote 8, at 55.
220. See id.
221. See id.
222. CRIPPS, supra note 161, at 124.
223. See Maryellen Fullerton, Enforcing Judicial Judgments Abroad: The Global
Challenge,24 BROOK. J. INT'L L. 1 (1998).
224. Id. at 1.
225. See TOEBES, supra note 193, at 154.
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and harm is seemingly immeasurable. It holds the promise of rooting out disease before it has a chance to manifest itself, while at
the same time, carrying with it the inevitable stigma of eugenic
practice. Human gene therapy is far too valuable a means of disease control and prevention to be suppressed by fears of abuse. It
is inescapable, however, that genetic experimentation has the potential to go unchecked and become a source of significant, longterm human rights violations. Moreover, genetic experimentation,
while capable of discovering new ways to treat and prevent disease, inherently alters the human genetic make-up.
On a large scale, inequitable application of this type of therapy carries with it the risk of creating genetically divergent evolutionary cultures. Surprisingly, given the global implications of this
experimental technology, there are currently no enforceable international regulations to protect against widespread abuses or significant alterations to the genetic code.
While this comment suggests specific methods for regulating
the application of human genetic technologies, it is by no means
comprehensive. It does, however, seek to address the nonexistent
state of effective international regulation of human genetic experimentation.
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